IOL Chemicals Reports 56% Rise in Q2 Profit; Shares Gain 13%

Shares of IOL Chemicals & Pharmaceuticals Ltd rose sharply on Wednesday, November 12, after the company announced its September quarter results, showing improved profitability and operational efficiency. The stock gained as much as 13% during the session, reversing its recent downward trend.

Revenue Growth and Margin Expansion

During the September quarter of FY25, the company reported a 56.3% year-on-year increase in net profit to ₹30 crore, compared to ₹19.2 crore in the same period last year. Revenue from operations rose by 8% to ₹567.5 crore, up from ₹525.8 crore a year ago. The company’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) also grew by 37% to ₹57 crore.

Operating margins expanded to 10% from 7.9% in the previous year’s quarter, supported by improved efficiency in production and a balanced product mix. The stronger profitability numbers contributed to renewed investor interest in the stock during midweek trading.

IOL Chemicals & Pharmaceuticals Share Price Performance

As of the latest trade, IOL Chemicals & Pharmaceuticals Share Price stood at ₹98.8, up 11.30% at 10:36 AM, on November 12, 2025. The stock, listed under BSE: 524164 and NSE: IOLCP, witnessed increased volumes following the announcement of the company’s quarterly performance.

The market capitalisation of the company is currently ₹2,900 crore. Over the past year, the stock has traded between a 52-week high of ₹127 and a low of ₹57.5. The company maintains a price-to-earnings (P/E) ratio of 25.0, a book value of ₹59.7, and a dividend yield of 0.79%. Its Return on Capital Employed (ROCE) stands at 8.86%, while the Return on Equity (ROE) is 6.13%.

Overview of Business Operations

Incorporated as a key player in both the pharmaceutical and specialty chemicals sectors, the company manufactures and supplies active pharmaceutical ingredients (APIs) and value-added chemical products for both domestic and international markets. It is one of the leading global manufacturers of Ibuprofen, with a world market share of approximately 35%.

Read More:NSDL Results Date Fixed Q2FY26 Earnings to Be Declared on November 13, 2025

Conclusion

The September quarter results reflect consistent growth across revenue and margins, signalling stable operational performance. The notable rise in profitability and improved margins supported investor sentiment, leading to gains in IOL Chemicals & Pharmaceuticals Share Price during the trading session.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.